Industry Updates for the Psychedelics World | Page 18 of 35

Psychedelics News

Industry

24 Oct 2022

Beckley Psytech Acquires Eleusis Therapeutics

Beckley Psytech Strengthens Pipeline and Development Team With Acquisition of Eleusis Therapeutics Limited...

By Microdose NewsDesk

Industry

20 Oct 2022

Microdose Announces Algernon Pharmaceuticals as Wonderland 2022 Headline Sponsor

It’s an honor for Microdose to announce Algernon Pharmaceuticals as the Headline Sponsor for Wonderland: Miami 2022....

By Microdose

Industry, Science

20 Oct 2022

A Deeper Look at Ketamine and its Potential for Addiction

Ketamine might be the current poster child for psychedelic medicine, but mainstream media has been missing an important reality about ketamine's divergence and potential for addiction....

By Patrick McConnell

Industry

19 Oct 2022

Small Pharma Expands IP With Another US Patent

This is the second United States Patent granted for Small Pharma’s psychedelics portfolio...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

17 Oct 2022

Top Reasons To Be At Wonderland 2022 (Part 1)

Wonderland 2021 successfully established the event as the go-to industry gathering....

By Microdose

Industry

13 Oct 2022

A Look at Web3 and Psychedelic IP

As companies move themselves toward potential commercialization of psychedelic medicines, a great deal of speculation and attention is being placed on intellectual property (IP) and the future of Web3....

By Patrick McConnell

Breaking News, Industry

12 Oct 2022

Breaking News: Compass Pathways to run TWO Phase 3 Trials for Depression

Today, psychedelic medicine company Compass Pathways (Nasdaq: CMPS) announced a major update: rather than conducting just one Phase 3 clinical trial attempting to treat Treatment-Resistant Depression (TRD) with psilocybin-assisted therapy,...

By James Hallifax

Industry

12 Oct 2022

Atai Announces Positive Phase 1 Results for Opioid Use Disorder

atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD...

By Microdose NewsDesk

Industry

12 Oct 2022

Convergence Partners Invests in Psychedelic CRO Clerkenwell Health

Convergence Partners is investing in the transformational psychedelic medicines sector by participating in the seed investment round of Clerkenwell Health Ltd....

By Microdose NewsDesk

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result